Evidence map›Paper›PMID 25995198›Full record

ArticleThe Journal of infectious diseases2015

T-Cell Depletion in the Colonic Mucosa of Patients With Idiopathic CD4+ Lymphopenia.

Stephen B Kovacs, Virginia Sheikh, William L Thompson, David R Morcock, Ainhoa Perez-Diez, Michael D Yao, Adam W Rupert, Netanya S Utay, Gregg Roby, Alexandra F Freeman and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  2. Trial
  3. Review
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Idiopathic CD4 Lymphocytopenia: Current Insights.ImmunoTargets and therapy · 2020
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Stephen B KovacsClinical Research Directorate/Clinical Monitoring Research Program.
Virginia SheikhNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
William L ThompsonNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
David R MorcockRetroviral Immunopathology Section, AIDS and Cancer Virus Program.
Ainhoa Perez-DiezNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Michael D YaoNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Adam W RupertAIDS Monitoring Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research.
Netanya S UtayDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston.
Gregg RobyNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Alexandra F FreemanNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Jacob D EstesRetroviral Immunopathology Section, AIDS and Cancer Virus Program.
Irini SeretiNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USPancreatic Cancer Action Network · USThe University of Texas Medical Branch at Galveston · US

Funding

Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) DiseaseZIAAI001121 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SERETI, IRINI · 2010 to 2025
$27.2M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Idiopathic CD4(+) lymphopenia (ICL) is a rare syndrome characterized by low peripheral CD4(+) T-cell counts that can lead to serious opportunistic infections. The pathogenesis of ICL remains unclear, and whether effector sites are also lymphopenic is unknown. In this study, rectosigmoid mucosal biopsy specimens from patients with ICL and healthy controls were evaluated. Significant T-cell lymphopenia was observed in the mucosal tissue of patients with ICL by flow cytometry and immunohistochemistry, compared with healthy controls. Functional capacity of T cells, assessed by production of interferon γ and interleukin 17, was preserved in the mucosa of patients with ICL. In contrast to T lymphocytes, the frequency of myeloid cells (neutrophils and macrophages) was elevated in the colonic mucosa of patients with ICL. Despite the observed mucosal abnormalities, plasma levels of intestinal fatty acid binding protein, a marker of enterocyte turnover and other inflammatory biomarkers, including interleukin 6, C-reactive protein, and tumor necrosis factor, were not elevated in patients with ICL, compared with healthy controls, whereas soluble CD14 levels were minimally elevated. These data suggest that patients with ICL, despite gut mucosal lymphopenia and local tissue inflammation, have preserved enterocyte turnover and T-helper type 17 cells with minimal systemic inflammation. These observations highlight differences from patients with human immunodeficiency virus infection, with or without AIDS, and may partially explain their distinct clinical prognosis.

Indexed as

Immune ToleranceAdultBiopsyCD4-Positive T-LymphocytesColonFemaleFlow CytometryHumansImmunohistochemistryInflammationIntestinal MucosaLymphopeniaMaleMiddle AgedbiomarkersHIV/AIDSidiopathic CD4+ lymphopeniainflammationmucosal immunity

Identifiers

PMID25995198
PMCPMC4621254
OpenAlexW1940518057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.